Vemurafenib Recruiting Phase 2 Trials for Hematologic Cancers / Metastatic Cancers / Tumors, Solid Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02304809Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations